Press Releases

September 12, 2022

BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine

Read Press Release Download PDF

March 22, 2022

BioMed Valley Discoveries Announces Poster Presentations on Ulixertinib (BVD-523) at the AACR Annual Meeting 2022

Read Press Release Download PDF

July 28, 2020

BioMed Valley Discoveries’ ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology

Read Press Release Download PDF

September 30, 2018

Bacterial Therapy Tolerable, Shows Early Promise in Patients With Advanced Solid Tumors

Read Press Release Download PDF

December 15, 2017

First-in-class ERK1/2 inhibitor safe, shows early efficacy in patients with advanced solid tumors

Read Press Release Download PDF

October 3, 2017

First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models

Read Press Release Download PDF

May 26, 2017

BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting

Read Press Release Download PDF

August 13, 2014

Bacterial biosurgery shows promise for reducing the size of inoperable tumors

Read Press Release Download PDF